Spur Therapeutics to Share Avigbagene Parvec Data at WORLDSymposium

LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene therapy candidate for Type 1 Gaucher disease, in platform and poster presentations at the 22nd Annual WORLDSymposiumTM being held February 2-6, 2026 in San Diego. Details of the platform presentation are below: Title: Two-year follow up of FLT201 AAV gene therapy in adults with Type 1 Gaucher Disease: Results from GALILEO-1 and GALILEO-2 Session: Clinical Applications Date & Time: Thursday, February 5, 9:30 a.m. PST Presenter: Ida Schwartz, MD, PhD, Hospital de Clinicas do Porto Alegre, Brazil An accompanying poster will be presented as part of the Clinical Applications Poster Session on Thursday, February 5, at 3:30 p.m. PST. Details of two additional poster presentations are below: Title: Individual Participant Outcomes After FLT201 AAV Gene Therapy for Type 1 Gaucher Disease: Two-Year Biomarker and Clinical Data Session: Clinical Applications Poster Session Date & Time: Thursday, February 5, at 3:30 p.m. PST Presenter: Ozlem Goker-Alpan, MD, Lysosomal and Rare Disorders Treatment Center, Virginia Title: Lyso-Gb1 Dynamics as a Surrogate Biomarker in Type 1 Gaucher Disease Treated with FLT201 AAV Gene Therapy Session: Clinical Applications Poster Session Date & Time: Thursday, February 5, at 3:30 p.m. PST Presenter: Simon Flynn, Spur Therapeutics Additional details on the meeting can be found at the WORLDSymposium website. About Spur Therapeutics Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions. By optimizing every component of its product candidates, Spur aims to unlock the true potential of gene therapy to realize outsized clinical results. Spur is advancing a breakthrough gene therapy candidate for Gaucher disease and disease and a preclinical gene therapy candidate for Parkinson’s disease. Expanding our impact, and advancing the practice of genetic medicine. Toward life-changing therapies, and brighter futures. Toward More™ For more information, visit www.spurtherapeutics.com or connect with Spur on LinkedIn. Contact Naomi Aoki naomi.aoki@spurtherapeutics.com + 1 617 283 4298